
NEWS
Milner – LifeArc strategic partnership extended for five years
We are thrilled to announce that the Milner collaboration with the medical research charity LifeArc has been expanded into a 5-year strategic...
Milner Institute wins award for innovation at Cambridge Independent Science and Technology Awards
We are honoured to have been announced as highly commended in the Innovation category of the 2022 Cambridge Independent Science & Technology...
Milner Institute announced as finalist in the Cambridge Independent Science and Technology Awards
We are delighted that the Milner Therapeutics Institute has been announced as a finalist for the Award for Innovation in the 2021-2022 Cambridge...
Milner Therapeutics Institute promoted to Affiliated Institute of CRUK Cambridge Centre
We are delighted to announce that, with the renewal of the CRUK Cambridge Centre this year, the Milner will become an Affiliated Institute,...
MTI welcomes George Freeman MP, to learn how Cambridge is leading innovation in life sciences
We were delighted to welcome George Freeman MP, the Parliamentary under Secretary of State in the Department for Business, Energy and Industrial...
Director Tony Kouzarides receives Cyprus Excellence in Science award
The President of Cyprus, Nicos Anastasiades, presented our Director Tony Kouzarides with the prestigious Excellence in Science Award this week, on...
Milner Institute wins OBN Award for Most Impactful Business Support Organisation
This week, Deputy Director Kathryn Chapman and Communications Manager Nikki Mann represented the Milner team at the OBN Awards in Oxford, and we are...
KPBMA bring international partners to Milner affiliate network
We are delighted to share that KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association) has joined as an Affiliated Organization of...
Astellas join Milner Therapeutics Consortium
We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global...
Milner Institute announced as finalist for OBN Award
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful...
Milner collaboration uncovers promising target for new drug development
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein...
Milner group use combination of computational biology and machine learning to create comprehensive map of proteins involved in SARS-CoV-2 infection
Namshik Han's group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to work against COVID-19 – of which only 40...
Connect: Health Tech is launched
We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite...
Onco-Innovation collaborations awarded from pump prime call
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid...
Milner collaboration targets RNA-modifying enzymes as promising anti-cancer strategy
Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a...
Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in...
Affiliate Companies showcase their work
As we reach the end of what has been the most challenging and difficult year so far, we want to take the time to celebrate the achievements of our...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the...
Start Codon closes new £15 million venture fund
Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed...
OncoInnovation: TGIO 2020 Challenge winner
Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early...
Kostas Tzelepis awarded John Goldman Fellowship
We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and...
Kathryn Lilley awarded EMBO membership
We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been...
Start Codon announces first cohort of companies
Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were...
Eisai join Milner Therapeutics Consortium
We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading...
Milner Institute illuminated blue for the NHS
The Jeffrey Cheah Biomedical Centre illuminated blue tonight, to honour the incredible work of our NHS. Milner Institute Director Professor Tony...
Milner seminars move online
We have been busy adapting plans for the coming months, and are pleased to announce that our Milner seminars are moving online. The first talk is...
Providing COVID-19 support
Thank you to the numerous Milner affiliated companies who have been in contact to offer support to the University and NHS at this time. Help tackle...
Milner Institute closure for COVID-19
As part of the response to COVID-19 at the University of Cambridge, the Milner Therapeutics Institute will be closed for non-essential business from...
Welcome to the Tzelepis Group
We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings...
A look inside the institute
For the past four years, the Milner Therapeutics Institute has been incubating in the Gurdon Institute – home to the research lab of our Director...
Launch of the Milner Therapeutics Institute
This month, we celebrated the launch of the Milner Therapeutics Institute in the Jeffrey Cheah Biomedical Centre. Key academics and consortium...
AstraZeneca-Cancer Research UK Functional Genomics Centre launch
We are excited to be celebrating the launch of the AstraZeneca-Cancer Research UK Functional Genomics Centre today. Based in the Milner Therapeutics...
Welcome to Cambridge Centre for Proteomics
A warm welcome to the team of Kathryn Lilley at the Cambridge Centre for Proteomics (CCP), who are moving into the Milner Therapeutics Institute...
First pre-competitive project initiated
A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using...
New University Enterprise Zone announced
The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by...
Welcome to Pathania group
We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a...
Renewal of Milner Therapeutics Consortium
We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex,...
New Opportunity for an Administrator and Finance Coordinator
Administrator and Finance Coordinator We are looking to appoint a new and key role in our brand new purpose built facilities in the Jeffrey Cheah...
Cambridge Biotech Week
The Milner Therapeutics Symposium 2019 is part of Cambridge Biotech Week (25-28th June), a festival of events focused on accelerating scientific...
Start Codon announced as new world-class life science accelerator
This innovative new accelerator programme will provide significant funding and support for selected start-ups, with office and lab space in the Milner Research Labs.
Milner Therapeutics Symposium 2019
Registration for the Milner Therapeutics Symposium on June 25th 2019 is now open! This Symposium is an opportunity for scientists from academia and...
Cancer Research UK and AstraZeneca launch world class functional genomics centre at the Milner Research Labs
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the Milner Research Labs in Cambridge, dedicated to...
Milner Therapeutics Symposium 2018
Our Annual Symposium is an opportunity for scientists from academia and industry to discuss the latest...
The Milner Institute’s Namshik Han takes part in a panel discussion at #Impact18
Computational Biology Programme Lead Namshik Han was on the panel at #Impact18 earlier this month, discussing how artificial intelligence is...
Milner facilitates strategic partnership between Nemesis and Shionogi
SHIONOGI INVESTS IN NEMESIS TECHNOLOGY Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience Nemesis Bioscience today...
Milner Affiliated company MedAnnex Ltd Receives SMART: SCOTLAND R&D Award
Scottish Enterprise will contribute up to £423,000 towards the industrial development of a novel antibody to treat autoimmune diseases Milner...
Registration is OPEN for The Milner Institute’s 2018 Symposium
Registration for The Milner Therapeutics Symposium is now open! This Symposium is an opportunity for scientists from academia and industry to...
The Milner Institute’s new building starts to take shape
Our new building is starting to take shape now, ready for the opening in October. The Milner Therapeutics Institute will have research...
LifeArc and Milner Therapeutics Institute announce a new partnership in artificial intelligence and machine learning for target discovery
London and Cambridge, UK 23 January 2018 – LifeArc®, the UK-based medical research charity and the Milner Therapeutics Institute at the University...
Genestack joins the Milner Therapeutics Institute
Genestack Press Release, 27 October 2017 “As sequencing technology shrinks to the size of a key ring and emerging technologies make it...